Recently, data from the British Society for Rheumatology's Biological Register (BSRBR) revealed that while the overall mortality was no different between anti-TNF-α agents and DMARDs, mortality from ILD was nearly tripled in patients on anti-TNF-α therapy compared to control patients on DMARDs alone [72]. Here, TNF is linked to interstitial lung disease.